P063 ELX/TEZ/IVA has beneficial effects on clinical outcomes and quality of life in people with cystic fibrosis in the real-world TRAJECTORY study.

Autor: Solé, A.¹ (AUTHOR), Ratjen, F.² (AUTHOR), Schwarz, C.³ (AUTHOR), Duckers, J.⁴ (AUTHOR), Azevedo, P.⁵ (AUTHOR), Daccò, V.⁶ (AUTHOR), Quon, B.S.⁷ (AUTHOR), Imaduddin Ahmed, M.⁸ (AUTHOR), Quintana, E.⁹ (AUTHOR), Gamboa, F.¹⁰ (AUTHOR), Cipolli, M.¹¹ (AUTHOR), McKinnon, C.¹² (AUTHOR), Heyne, M.¹² (AUTHOR), Scirica, C.¹² (AUTHOR), Sutharsan, S.¹³ (AUTHOR)

Publikováno v: Journal of Cystic Fibrosis. 2024 Supplement 1, Vol. 23, pS85-S86. 2p.